Keyword: Ozempic (semaglutide)

After Novo Nordisk secures U.S. access for Rybelsus, it'll be time to go into "strike mode" with full promotion, its CEO said.

ICER concluded that Novo Nordisk's diabetes pill Rybelsus will be less cost-effective than Jardiance as an add-on therapy in type 2 diabetes.

Monday, Bernstein analysts echoed what many were probably thinking about Novo Nordisk’s Rybelsus price: “Finally we can stop talking about it.”

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

New real-world data from Lilly and BI show their SGLT2 med Jardiance topped GLP-1s at preventing heart failure hospitalization.

Novo Nordisk’s Ozempic is off to a blazing start, and the company just threw more fuel on the fire with a pair of trial wins.

Heart benefits offered by Novo Nordisk's oral version of its hit drug for Type 2 diabetes, Ozempic, won't justify its price, ICER said.

Ahead of another big launch, Novo's new GLP-1 med Ozempic is scooping up market share. And with its insulins suffering, that's a welcome relief.

Novo Nordisk may have already submitted its approval application for its oral GLP-1 drug semaglutide, but the deluge of positive data hasn’t stopped.

Skeptical Eli Lilly investors may wonder whether Trulicity's cardiovascular outcomes performance can fend off competition from Novo Nordisk.